Aurobindo Pharma's subsidiary, CuraTeQ Biologics, has received a GMP certificate from the European Medicines Agency for its ...
EBR Systems is among ASX healthcare stocks with upcoming catalysts, expecting feedback on a FDA substantive review expected ...
Eseba-vec has received Fast Track Designation from the U.S. Food and Drug Administratin and PRIME designation from the European Medicines Agency for the treatment of 1L HPV16+ OPSCC. Eseba-vec was ...
Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.
Global health is likely to be radically altered with Donald Trump in the White House. For starters, the president-elect has ...
Panax ginseng shows highest effectiveness in treating Alzheimer's. Learn more about AVXL's blarcamesine and SAVA's simufilam ...
A fatal, highly hereditary illness with no disease-modifying treatments, Huntington’s is long overdue for a therapeutic win.
The past four years have brought disappointment for the Huntington’s community, but optimism is growing as companies ...
Neurizon has been buoyed by the receipt of a positive opinion from the European Medicines Agency in relation to its ... Read ...
While the final decision is set for next month, biotech player Neurizon’s (ASX:NUZ) hopes have been lifted with a view ...
Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®â–¼ (erdafitinib) as a monotherapy for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback